VIJAYPD

VijayPD Ceutical Share Price

 

 

Start SIP in VIJAYPD

Start SIP
VijayPD Ceutical live price: ₹71.25. It opened at ₹70 vs previous close ₹70; intraday high/low: ₹73/₹67. The 50 DMA stands at ₹56.92.

VijayPD Ceutical Performance

  • Low
  • ₹67
  • High
  • ₹73
  • 52 Week Low
  • ₹35
  • 52 Week High
  • ₹74
  • Open Price₹70
  • Previous Close₹70
  • Volume84,000
  • 50 DMA₹56.92
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month + 15.11%
  • Over 3 Month + 57.98%
  • Over 6 Month + 103.57%
  • Over 1 Year + 103.57%

Smart Investing Starts Here Start SIP with VijayPD Ceutical for Steady Growth!

Invest Now

VijayPD Ceutical Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29
  • PEG Ratio
  • -
  • Market Cap Cr
  • 139
  • P/B Ratio
  • 3.5
  • Average True Range
  • 4.13
  • EPS
  • 2.46
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.91
  • RSI
  • 65.81
  • MFI
  • 59.41

VijayPD Ceutical Financials

VijayPD Ceutical Technicals

EMA & SMA

Current Price
₹71.25
+ 1.25 (1.79%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 11
  • 20 Day
  • ₹63.62
  • 50 Day
  • ₹56.92
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

70.4 Pivot Speed
  • R3 81.10
  • R2 77.25
  • R1 74.25
  • S1 67.40
  • S2 63.55
  • S3 60.55

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

VijayPD Ceutical Ltd is a trusted pharmaceutical wholesaler with over 50 years of experience. Guided by values of service, respect, and excellence, it delivers a wide range of healthcare products and solutions, supporting pharmacies and improving patient outcomes nationwide.

Vijaypd Ceutical Ltd has an operating revenue of Rs. 262.80 Cr. on a trailing 12-month basis. An annual revenue growth of 98% is outstanding, Pre-tax margin of 6% is okay, ROE of 14% is good. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 32% and 41% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 26% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 160 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

VijayPD Ceutical Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results & Others To consider other business matters

VijayPD Ceutical F&O

VijayPD Ceutical Shareholding Pattern

56.25%
39%
4.75%

About VijayPD Ceutical

  • NSE Symbol
  • VIJAYPD
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Samit Madhukar Shah
  • ISIN
  • INE0WL901019

Similar Stocks to VijayPD Ceutical

VijayPD Ceutical FAQs

VijayPD Ceutical share price is ₹71 As on 15 March, 2026 | 15:28

The Market Cap of VijayPD Ceutical is ₹139.1 Cr As on 15 March, 2026 | 15:28

The P/E ratio of VijayPD Ceutical is 29 As on 15 March, 2026 | 15:28

The PB ratio of VijayPD Ceutical is 3.5 As on 15 March, 2026 | 15:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23